Essential Partners’s Mersana Therapeutics MRSN Stock Holding History

Essential Partners’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82	Closed	-$2.37K	–	2940
2025 Q4	$2.37K	Sell	82 -34	-29%	-$646	﹤0.01%	1742
2025 Q3	$900	Sell	116 -100	-46%	-$750	﹤0.01%	2051
2025 Q2	$1.6K	Buy	+216	New	+$1.9K	﹤0.01%	1382

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Essential Partners's MRSN Position: Q1 2026 in Review

Essential Partners sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 82 shares — an estimated $2.37K sold.

Essential Partners first reported a position in MRSN in Q2 2025 and held it in 3 quarters. The position peaked at $2.37K in Q4 2025. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

Essential Partners reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
Essential Partners sold 82 Mersana Therapeutics shares in Q1 2026, an estimated $2.37K.
Essential Partners first reported a position in Mersana Therapeutics in Q2 2025 and held it in 3 quarters.
Essential Partners's Mersana Therapeutics position peaked at $2.37K in Q4 2025.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.